Pregnancy after Breast Cancer: Myths and Facts

Por Pagani, Olivia, Azim, Hatem
Publicado em 2012

Clear Cell Carcinoma of the Breast: A Rare Breast Cancer Subtype – Case Report and Literature Review

Por Ratti, Vilma, Pagani, Olivia
Publicado no Case Rep Oncol (2015)

The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer

Por Rossi, Lorenzo, Pagani, Olivia
Publicado no Breast Care (Basel) (2015)

Oligometastatic Breast Cancer: A Shift from Palliative to Potentially Curative Treatment?

Por Di Lascio, Simona, Pagani, Olivia
Publicado em 2014

Hormonal therapies in young breast cancer patients: when, what and for how long?

Por Christinat, Alexandre, Di Lascio, Simona, Pagani, Olivia
Publicado em 2013

Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93

Por Pagani, Olivia, Gelber, Shari, Colleoni, Marco, Price, Karen N., Simoncini, Edda
Publicado em 2013

International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?

Por Pagani, Olivia, Senkus, Elżbieta, Wood, William, Colleoni, Marco, Cufer, Tanja, Kyriakides, Stella, Costa, Alberto, Winer, Eric P., Cardoso, Fatima
Publicado em 2010

International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy

Por Cardoso, Fatima, Bedard, Philippe L., Winer, Eric P., Pagani, Olivia, Senkus-Konefka, Elzbieta, Fallowfield, Lesley J., Kyriakides, Stella, Costa, Alberto, Cufer, Tanja, Albain, Kathy S.
Publicado em 2009

Second non-breast primary cancer following adjuvant therapy for early breast cancer: A report from the International Breast Cancer Study Group

Por Gianni, Lorenzo, Gelber, Shari, Ravaioli, Alberto, Price, Karen N., Panzini, Ilaria, Fantini, Manuela, Castiglione-Gertsch, Monica, Pagani, Olivia, Simoncini, Edda, Gelber, Richard D., Coates, Alan S., Goldhirsch, Aron
Publicado em 2008

Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century

Por Pagani, Olivia, Price, Karen N., Gelber, Richard D., Castiglione-Gertsch, Monica, Holmberg, Stig B., Lindtner, Jurij, Thürlimann, Beat, Collins, John, Fey, Martin F., Coates, Alan S., Goldhirsch, Aron
Publicado em 2009

Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial

Por Phillips, Kelly Anne, Ribi, Karin, Sun, Zhuoxin, Stephens, Alisa, Thompson, Alastair, Harvey, Vernon, Thürlimann, Beat, Cardoso, Fatima, Pagani, Olivia, Coates, Alan S., Goldhirsch, Aron, Price, Karen N., Gelber, Richard D., Bernhard, Jürg
Publicado em 2010

Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

Por Phillips, Kelly-Anne, Aldridge, Julie, Ribi, Karin, Sun, Zhuoxin, Thompson, Alastair, Harvey, Vernon, Thürlimann, Beat, Cardoso, Fatima, Pagani, Olivia, Coates, Alan S., Goldhirsch, Aron, Price, Karen N., Gelber, Richard D., Bernhard, Jürg
Publicado em 2010

Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials

Por Regan, Meredith M., Pagani, Olivia, Fleming, Gini F., Walley, Barbara A., Price, Karen N., Rabaglio, Manuela, Maibach, Rudolf, Ruepp, Barbara, Coates, Alan S., Goldhirschi, Aron, Colleoni, Marco, Gelber, Richard D., Francisl, Prudence A.
Publicado em 2013

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT...

Por Regan, Meredith M., Francis, Prudence A., Pagani, Olivia, Fleming, Gini F., Walley, Barbara A., Viale, Giuseppe, Colleoni, Marco, Láng, István, Gómez, Henry L., Tondini, Carlo, Pinotti, Graziella, Price, Karen N., Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D.
Publicado no J Clin Oncol (2016)

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Canc...

Por Pagani, Olivia, Gelber, Shari, Simoncini, Edda, Castiglione-Gertsch, Monica, Price, Karen N., Gelber, Richard D., Holmberg, Stig B., Crivellari, Diana, Collins, John, Lindtner, Jurij, Thürlimann, Beat, Fey, Martin F., Murray, Elizabeth, Forbes, John F., Coates, Alan S., Goldhirsch, Aron
Publicado em 2008

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

Por Johansson, Harriet, Gray, Kathryn P., Pagani, Olivia, Regan, Meredith M., Viale, Giuseppe, Aristarco, Valentina, Macis, Debora, Puccio, Antonella, Roux, Susanne, Maibach, Rudolf, Colleoni, Marco, Rabaglio, Manuela, Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Kammler, Roswitha, Bonanni, Bernardo, Walley, Barbara A.
Publicado no Breast Cancer Res (2016)

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

Por Regan, Meredith M., Leyland-Jones, Brian, Bouzyk, Mark, Pagani, Olivia, Tang, Weining, Kammler, Roswitha, Dell’Orto, Patrizia, Biasi, Maria Olivia, Thürlimann, Beat, Lyng, Maria B., Ditzel, Henrik J., Neven, Patrick, Debled, Marc, Maibach, Rudolf, Price, Karen N., Gelber, Richard D., Coates, Alan S., Goldhirsch, Aron, Rae, James M., Viale, Giuseppe
Publicado em 2012

Adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression: patient-reported outcomes in the TEXT and SOFT randomised trial...

Por Bernhard, Jürg, Luo, Weixiu, Ribi, Karin, Colleoni, Marco, Burstein, Harold J., Tondini, Carlo, Pinotti, Graziella, Spazzapan, Simon, Ruhstaller, Thomas, Puglisi, Fabio, Pavesi, Lorenzo, Parmar, Vani, Regan, Meredith M., Pagani, Olivia, Fleming, Gini F., Francis, Prudence A., Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Walley, Barbara A.
Publicado no Lancet Oncol (2015)

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

Por Leyland-Jones, Brian, Gray, Kathryn P., Abramovitz, Mark, Bouzyk, Mark, Young, Brandon, Long, Bradley, Kammler, Roswitha, Dell’Orto, Patrizia, Biasi, Maria Olivia, Thürlimann, Beat, Harvey, Vernon, Neven, Patrick, Arnould, Laurent, Maibach, Rudolf, Price, Karen N., Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Pagani, Olivia, Viale, Giuseppe, Rae, James M., Regan, Meredith M.
Publicado no Breast Cancer Res Treat (2015)

Predictive value and clinical utility of centrally-assessed ER, PgR and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-nega...

Por Regan, Meredith M., Pagani, Olivia, Francis, Prudence A., Fleming, Gini F., Walley, Barbara A., Kammler, Roswitha, Dell'Orto, Patrizia, Russo, Leila, Szőke, János, Doimi, Franco, Villani, Laura, Pizzolitto, Stefano, Öhlschlegel, Christian, Sessa, Fausto, Cámara, Vicente Peg, Peralto, José Luis Rodríguez, MacGrogan, Gaëtan, Colleoni, Marco, Goldhirsch, Aron, Price, Karen N., Coates, Alan S., Gelber, Richard D., Viale, Giuseppe
Publicado no Breast Cancer Res Treat (2015)